Literature DB >> 25838296

Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic.

Mark Kester, Jocelyn Bassler, Todd E Fox, Carly J Carter, Jeff A Davidson, Mylisa R Parette.   

Abstract

Despite the therapeutic potential of sphingolipids, the ability to develop this class of compounds as active pharmaceutical ingredients has been hampered by issues of solubility and delivery. Beyond these technical hurdles, significant challenges in completing the necessary preclinical studies to support regulatory review are necessary for commercialization. This review seeks to identify the obstacles and potential solutions in the translation of a novel liposomal technology from the academic bench to investigational new drug (IND) stage by discussing the preclinical development of the Ceramide NanoLiposome (CNL), which is currently being developed as an anticancer drug for the initial indication of hepatocellular carcinoma (HCC).

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838296     DOI： 10.1515/hsz-2015-0129

Source DB:  PubMed          Journal:  Biol Chem        ISSN： 1431-6730            Impact factor:   3.915


  24 in total

Review 1.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

2.  Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia.

Authors:  Brian M Barth; Weiyuan Wang; Paul T Toran; Todd E Fox; Charyguly Annageldiyev; Regina M Ondrasik; Nicole R Keasey; Timothy J Brown; Viola G Devine; Emily C Sullivan; Andrea L Cote; Vasiliki Papakotsi; Su-Fern Tan; Sriram S Shanmugavelandy; Tye G Deering; David B Needle; Stephan T Stern; Junjia Zhu; Jason Liao; Aaron D Viny; David J Feith; Ross L Levine; Hong-Gang Wang; Thomas P Loughran; Arati Sharma; Mark Kester; David F Claxton
Journal:  Blood Adv       Date:  2019-09-10

3.  Functions of neutral ceramidase in the Golgi apparatus.

Authors:  Wataru Sakamoto; Nicolas Coant; Daniel Canals; Lina M Obeid; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-08-28       Impact factor: 5.922

Review 4.  Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.

Authors:  E Ramsay Camp; Logan D Patterson; Mark Kester; Christina Voelkel-Johnson
Journal:  Cancer Biol Ther       Date:  2017-07-07       Impact factor: 4.742

5.  Influence of ceramide on lipid domain stability studied with small-angle neutron scattering: The role of acyl chain length and unsaturation.

Authors:  Mitchell DiPasquale; Tye G Deering; Dhimant Desai; Arun K Sharma; Shantu Amin; Todd E Fox; Mark Kester; John Katsaras; Drew Marquardt; Frederick A Heberle
Journal:  Chem Phys Lipids       Date:  2022-04-26       Impact factor: 3.570

6.  Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome-Induced Cell Death in Head and Neck Squamous Cell Carcinoma.

Authors:  Jeremy J P Shaw; Timothy L Boyer; Emily Venner; Patrick J Beck; Tristen Slamowitz; Tara Caste; Alexandra Hickman; Michael H Raymond; Pedro Costa-Pinheiro; Mark J Jameson; Todd E Fox; Mark Kester
Journal:  Mol Cancer Ther       Date:  2020-10-21       Impact factor: 6.261

7.  Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia.

Authors:  Samy A F Morad; Terence E Ryan; P Darrell Neufer; Tonya N Zeczycki; Traci S Davis; Matthew R MacDougall; Todd E Fox; Su-Fern Tan; David J Feith; Thomas P Loughran; Mark Kester; David F Claxton; Brian M Barth; Tye G Deering; Myles C Cabot
Journal:  J Lipid Res       Date:  2016-05-02       Impact factor: 5.922

8.  Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer.

Authors:  Xuewei Zhang; Kazuyuki Kitatani; Masafumi Toyoshima; Masumi Ishibashi; Toshinori Usui; Junko Minato; Mahy Egiz; Shogo Shigeta; Todd Fox; Tye Deering; Mark Kester; Nobuo Yaegashi
Journal:  Mol Cancer Ther       Date:  2017-10-27       Impact factor: 6.261

9.  Conjugation of peptides to short-acyl-chain ceramides for delivery across mucosal cell barriers.

Authors:  Richard I Duclos; Kiara D Blue; Michael J Rufo; Xiaoling Chen; Jason J Guo; Xiaoyu Ma; Wayne I Lencer; Daniel J F Chinnapen
Journal:  Bioorg Med Chem Lett       Date:  2020-02-07       Impact factor: 2.823

10.  Ceramide synthase 2-C24:1 -ceramide axis limits the metastatic potential of ovarian cancer cells.

Authors:  Xuewei Zhang; Wataru Sakamoto; Daniel Canals; Masumi Ishibashi; Masaya Matsuda; Kentaro Nishida; Masafumi Toyoshima; Shogo Shigeta; Makoto Taniguchi; Can E Senkal; Toshiro Okazaki; Nobuo Yaegashi; Yusuf A Hannun; Takeshi Nabe; Kazuyuki Kitatani
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.